Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers

Joanne Kotsopoulos, Jan Lubinski, Pal Moller, Henry T. Lynch, Christian F. Singer, Charis Eng, Susan L. Neuhausen, Beth Karlan, Charmaine Kim-Sing, Tomasz Huzarski, Jacek Gronwald, Jeanna McCuaig, Leigha Senter, Nadine Tung, Parviz Ghadirian, Andrea Eisen, Dawna Gilchrist, Joanne L. Blum, Dana Zakalik, Tuya PalPing Sun, Steven A. Narod

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

It is not clear if early oral contraceptive use increases the risk of breast cancer among young women with a breast cancer susceptibility gene 1 (BRCA1) mutation. Given the benefit of oral contraceptives for the prevention of ovarian cancer, estimating age-specific risk ratios for oral contraceptive use and breast cancer is important. We conducted a case-control study of 2,492 matched pairs of women with a deleterious BRCA1 mutation. Breast cancer cases and unaffected controls were matched on year of birth and country of residence. Detailed information about oral contraceptive use was collected from a routinely administered questionnaire. Conditional logistic regression was used to estimate the odds ratios (OR) and 95 % confidence intervals (CI) for the association between oral contraceptive and breast cancer, by age at first use and by age at diagnosis. Among BRCA1 mutation carriers, oral contraceptive use was significantly associated with an increased risk of breast cancer for women who started the pill prior to age 20 (OR 1.45; 95 % CI 1.20-1.75; P = 0.0001) and possibly between ages 20 and 25 as well (OR 1.19; 95 % CI 0.99-1.42; P = 0.06). The effect was limited to breast cancers diagnosed before age 40 (OR 1.40; 95 % CI 1.14-1.70; P = 0.001); the risk of early-onset breast cancer increased by 11 % with each additional year of pill use when initiated prior to age 20 (OR 1.11; 95 % CI 1.03-1.20; P = 0.008). There was no observed increase for women diagnosed at or after the age of 40 (OR 0.97; 95 % CI 0.79-1.20; P = 0.81). Oral contraceptive use before age 25 increases the risk of early-onset breast cancer among women with a BRCA1 mutation and the risk increases with duration of use. Caution should be taken when advising women with a BRCA1 mutation to take an oral contraceptive prior to age 25.

Original languageEnglish
Pages (from-to)579-586
Number of pages8
JournalBreast Cancer Research and Treatment
Volume143
Issue number3
DOIs
StatePublished - Feb 2014

Fingerprint

Neoplasm Genes
Oral Contraceptives
Breast Neoplasms
Mutation
Odds Ratio
Confidence Intervals
Mouth Neoplasms
Ovarian Neoplasms
Case-Control Studies
Logistic Models

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. / Kotsopoulos, Joanne; Lubinski, Jan; Moller, Pal; Lynch, Henry T.; Singer, Christian F.; Eng, Charis; Neuhausen, Susan L.; Karlan, Beth; Kim-Sing, Charmaine; Huzarski, Tomasz; Gronwald, Jacek; McCuaig, Jeanna; Senter, Leigha; Tung, Nadine; Ghadirian, Parviz; Eisen, Andrea; Gilchrist, Dawna; Blum, Joanne L.; Zakalik, Dana; Pal, Tuya; Sun, Ping; Narod, Steven A.

In: Breast Cancer Research and Treatment, Vol. 143, No. 3, 02.2014, p. 579-586.

Research output: Contribution to journalArticle

Kotsopoulos, J, Lubinski, J, Moller, P, Lynch, HT, Singer, CF, Eng, C, Neuhausen, SL, Karlan, B, Kim-Sing, C, Huzarski, T, Gronwald, J, McCuaig, J, Senter, L, Tung, N, Ghadirian, P, Eisen, A, Gilchrist, D, Blum, JL, Zakalik, D, Pal, T, Sun, P & Narod, SA 2014, 'Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers', Breast Cancer Research and Treatment, vol. 143, no. 3, pp. 579-586. https://doi.org/10.1007/s10549-013-2823-4
Kotsopoulos, Joanne ; Lubinski, Jan ; Moller, Pal ; Lynch, Henry T. ; Singer, Christian F. ; Eng, Charis ; Neuhausen, Susan L. ; Karlan, Beth ; Kim-Sing, Charmaine ; Huzarski, Tomasz ; Gronwald, Jacek ; McCuaig, Jeanna ; Senter, Leigha ; Tung, Nadine ; Ghadirian, Parviz ; Eisen, Andrea ; Gilchrist, Dawna ; Blum, Joanne L. ; Zakalik, Dana ; Pal, Tuya ; Sun, Ping ; Narod, Steven A. / Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. In: Breast Cancer Research and Treatment. 2014 ; Vol. 143, No. 3. pp. 579-586.
@article{38fa15d564e349e0b10e7ffd9f3b854f,
title = "Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers",
abstract = "It is not clear if early oral contraceptive use increases the risk of breast cancer among young women with a breast cancer susceptibility gene 1 (BRCA1) mutation. Given the benefit of oral contraceptives for the prevention of ovarian cancer, estimating age-specific risk ratios for oral contraceptive use and breast cancer is important. We conducted a case-control study of 2,492 matched pairs of women with a deleterious BRCA1 mutation. Breast cancer cases and unaffected controls were matched on year of birth and country of residence. Detailed information about oral contraceptive use was collected from a routinely administered questionnaire. Conditional logistic regression was used to estimate the odds ratios (OR) and 95 {\%} confidence intervals (CI) for the association between oral contraceptive and breast cancer, by age at first use and by age at diagnosis. Among BRCA1 mutation carriers, oral contraceptive use was significantly associated with an increased risk of breast cancer for women who started the pill prior to age 20 (OR 1.45; 95 {\%} CI 1.20-1.75; P = 0.0001) and possibly between ages 20 and 25 as well (OR 1.19; 95 {\%} CI 0.99-1.42; P = 0.06). The effect was limited to breast cancers diagnosed before age 40 (OR 1.40; 95 {\%} CI 1.14-1.70; P = 0.001); the risk of early-onset breast cancer increased by 11 {\%} with each additional year of pill use when initiated prior to age 20 (OR 1.11; 95 {\%} CI 1.03-1.20; P = 0.008). There was no observed increase for women diagnosed at or after the age of 40 (OR 0.97; 95 {\%} CI 0.79-1.20; P = 0.81). Oral contraceptive use before age 25 increases the risk of early-onset breast cancer among women with a BRCA1 mutation and the risk increases with duration of use. Caution should be taken when advising women with a BRCA1 mutation to take an oral contraceptive prior to age 25.",
author = "Joanne Kotsopoulos and Jan Lubinski and Pal Moller and Lynch, {Henry T.} and Singer, {Christian F.} and Charis Eng and Neuhausen, {Susan L.} and Beth Karlan and Charmaine Kim-Sing and Tomasz Huzarski and Jacek Gronwald and Jeanna McCuaig and Leigha Senter and Nadine Tung and Parviz Ghadirian and Andrea Eisen and Dawna Gilchrist and Blum, {Joanne L.} and Dana Zakalik and Tuya Pal and Ping Sun and Narod, {Steven A.}",
year = "2014",
month = "2",
doi = "10.1007/s10549-013-2823-4",
language = "English",
volume = "143",
pages = "579--586",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers

AU - Kotsopoulos, Joanne

AU - Lubinski, Jan

AU - Moller, Pal

AU - Lynch, Henry T.

AU - Singer, Christian F.

AU - Eng, Charis

AU - Neuhausen, Susan L.

AU - Karlan, Beth

AU - Kim-Sing, Charmaine

AU - Huzarski, Tomasz

AU - Gronwald, Jacek

AU - McCuaig, Jeanna

AU - Senter, Leigha

AU - Tung, Nadine

AU - Ghadirian, Parviz

AU - Eisen, Andrea

AU - Gilchrist, Dawna

AU - Blum, Joanne L.

AU - Zakalik, Dana

AU - Pal, Tuya

AU - Sun, Ping

AU - Narod, Steven A.

PY - 2014/2

Y1 - 2014/2

N2 - It is not clear if early oral contraceptive use increases the risk of breast cancer among young women with a breast cancer susceptibility gene 1 (BRCA1) mutation. Given the benefit of oral contraceptives for the prevention of ovarian cancer, estimating age-specific risk ratios for oral contraceptive use and breast cancer is important. We conducted a case-control study of 2,492 matched pairs of women with a deleterious BRCA1 mutation. Breast cancer cases and unaffected controls were matched on year of birth and country of residence. Detailed information about oral contraceptive use was collected from a routinely administered questionnaire. Conditional logistic regression was used to estimate the odds ratios (OR) and 95 % confidence intervals (CI) for the association between oral contraceptive and breast cancer, by age at first use and by age at diagnosis. Among BRCA1 mutation carriers, oral contraceptive use was significantly associated with an increased risk of breast cancer for women who started the pill prior to age 20 (OR 1.45; 95 % CI 1.20-1.75; P = 0.0001) and possibly between ages 20 and 25 as well (OR 1.19; 95 % CI 0.99-1.42; P = 0.06). The effect was limited to breast cancers diagnosed before age 40 (OR 1.40; 95 % CI 1.14-1.70; P = 0.001); the risk of early-onset breast cancer increased by 11 % with each additional year of pill use when initiated prior to age 20 (OR 1.11; 95 % CI 1.03-1.20; P = 0.008). There was no observed increase for women diagnosed at or after the age of 40 (OR 0.97; 95 % CI 0.79-1.20; P = 0.81). Oral contraceptive use before age 25 increases the risk of early-onset breast cancer among women with a BRCA1 mutation and the risk increases with duration of use. Caution should be taken when advising women with a BRCA1 mutation to take an oral contraceptive prior to age 25.

AB - It is not clear if early oral contraceptive use increases the risk of breast cancer among young women with a breast cancer susceptibility gene 1 (BRCA1) mutation. Given the benefit of oral contraceptives for the prevention of ovarian cancer, estimating age-specific risk ratios for oral contraceptive use and breast cancer is important. We conducted a case-control study of 2,492 matched pairs of women with a deleterious BRCA1 mutation. Breast cancer cases and unaffected controls were matched on year of birth and country of residence. Detailed information about oral contraceptive use was collected from a routinely administered questionnaire. Conditional logistic regression was used to estimate the odds ratios (OR) and 95 % confidence intervals (CI) for the association between oral contraceptive and breast cancer, by age at first use and by age at diagnosis. Among BRCA1 mutation carriers, oral contraceptive use was significantly associated with an increased risk of breast cancer for women who started the pill prior to age 20 (OR 1.45; 95 % CI 1.20-1.75; P = 0.0001) and possibly between ages 20 and 25 as well (OR 1.19; 95 % CI 0.99-1.42; P = 0.06). The effect was limited to breast cancers diagnosed before age 40 (OR 1.40; 95 % CI 1.14-1.70; P = 0.001); the risk of early-onset breast cancer increased by 11 % with each additional year of pill use when initiated prior to age 20 (OR 1.11; 95 % CI 1.03-1.20; P = 0.008). There was no observed increase for women diagnosed at or after the age of 40 (OR 0.97; 95 % CI 0.79-1.20; P = 0.81). Oral contraceptive use before age 25 increases the risk of early-onset breast cancer among women with a BRCA1 mutation and the risk increases with duration of use. Caution should be taken when advising women with a BRCA1 mutation to take an oral contraceptive prior to age 25.

UR - http://www.scopus.com/inward/record.url?scp=84894057159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894057159&partnerID=8YFLogxK

U2 - 10.1007/s10549-013-2823-4

DO - 10.1007/s10549-013-2823-4

M3 - Article

C2 - 24458845

AN - SCOPUS:84894057159

VL - 143

SP - 579

EP - 586

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -